# US 2011/0087022 A1 · Dipeptidyl Peptidase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0087022 A1
- Document ID: US20110087022A1
- Status: Published application
- Kind: A1
- Application number: 12/964,410
- Filed: 2010-12-09
- Published: 2011-04-14
- Earliest claimed: 2004-12-21
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Jun Feng; Stephen L. Gwaltney, II; Jeffrey A. Stafford; Michael B. Wallace; Zhiyuan Zhang
- Web page: https://patentgrep.com/patent/US20110087022A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 487/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a member selected from the group consisting of: wherein E is CH or N, Q is selected from the group consisting of CO, CS, SO, SO2, or C═NR4, and L, X, Z, R2 and R3 are as defined herein.

## Claims

### Claim 1

A compound comprising a member selected from the group consisting of:
wherein
E is N;
Q is CO;
-MR19 is:
p is 0-10;
each R8 is independently selected from the group consisting of halo, cyano, nitro, alkyl, and amino;
R2 and R3 are taken together to form a 5 or 6 membered ring consisting of atoms selected from the group of carbon, nitrogen, oxygen and sulfur;
L is an unsubstituted (C1-10)alkylene or a (C1-10)alkylene substituted by a moiety selected from the group consisting of substituted or unsubstituted (C1-10)alkyl, a substituted or unsubstituted (C1-10)alkoxy, cyano and halo; and
X is an unsubstituted aryl or an aryl substituted by a non-hydrogen substituent selected from the group consisting of (C1-10)alkyl, cyano, nitro, and halo.

### Claim at position 2

2-10. (canceled)

### Claim 11 (depends on 1)

The compound according to claim 1, wherein at least one R8 is a primary, secondary, or tertiary amine.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound according to claim 1, wherein at least one R8 is selected from the group consisting of —NH2, —NH(C1-5 alkyl), and —N(C1-5 alkyl)2.

### Claim at position 6

14-18. (canceled)

### Claim 19 (depends on 1)

The compound according to claim 1, wherein L is a (C1-3)alkylene.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The compound according to claim 1, wherein L is a (C1)alkylene.

### Claim at position 10

22-31. (canceled)

### Claim 32 (depends on 1)

The compound according to claim 1, wherein L is selected from the group consisting of —CH2—, —CHR12—, and —C(R12)(R12′)— where R12 and R12′ are each independently selected from the group consisting of hydrogen, cyano, substituted or unsubstituted (C1-10)alkyl, substituted or unsubstituted alkoxy and halo.

### Claim 33 (depends on 1)

The compound according to claim 1, wherein L is selected from the group consisting of —CH2—, —CH2CH2—, and —CH2CH2CH2.

### Claim at position 13

34-40. (canceled)

### Claim 41 (depends on 1)

The compound according to claim 1, wherein X is a substituted or unsubstituted phenyl wherein the substituent is selected from the group consisting of (C1-10)alkyl, cyano, nitro and halo.

### Claim 42

(canceled)

### Claim 43 (depends on 1)

The compound according to claim 1, wherein X is an aryl having a non-hydrogen substituent at a 2 or 3 position.

### Claim 44 (depends on 1)

The compound according to claim 1, wherein X has a non-hydrogen substituent at a 2 or 3 position of the ring wherein the non-hydrogen substituent is selected from the group consisting of (C1-10)alkyl cyano, nitro, and halo.

### Claim 45 (depends on 1)

The compound according to claim 1, wherein X is selected from the group consisting of (2-cyano)phenyl, (3-cyano)phenyl, (2-nitro)phenyl, and (3-nitro)phenyl.

### Claim 46

(canceled)

### Claim 47 (depends on 1)

The compound according to claim 1, wherein
X is selected from the group consisting of:
t is 0, 1, 2, or 3; and
each R7 is independently selected from the group consisting of halo, (C1-10)alkyl, cyano, and nitro.

### Claim at position 21

48-51. (canceled)

### Claim 52 (depends on 1)

The compound according to claim 1, wherein -LX is selected from the group consisting of —(CH2)-(2-cyano)phenyl and —(CH2)-(3-cyano)phenyl.

### Claim 53 (depends on 1)

The compound according to claim 1, wherein -LX is a substituted or unsubstituted —(C1)alkylene-aryl wherein the substituent is selected from the group consisting of (C1-10)alkyl, cyano, nitro and halo.

### Claim at position 24

54-82. (canceled)

### Claim 83 (depends on 1)

The compound according to claim 1, wherein the compound is in the form of a pharmaceutically acceptable salt.

### Claim 84 (depends on 1)

The compound according to claim 1, wherein the compound is present in a mixture of stereoisomers.

### Claim 85 (depends on 1)

The compound according to claim 1, wherein the compound comprises a single stereoisomer.

### Claim 86

A compound selected from the group consisting of:
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-3H-imidazo[1,2-a][1,3,5]triazin-4-one;
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-3,6-dihydro-pyrimido[1,6-a][1,3,5]triazin-4-one;
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-5,6,8,8a-tetrahydro-3H-7-oxa-1,3,4a-triaza-naphthalen-4-one;
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-5,6,8,8a-tetrahydro-3H-7-thia-1,3,4a-triaza-naphthalen-4-one;
(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one;
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-3H-imidazo[1,5-a][1,3,5]triazin-4-one;
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-3,6-dihydro-pyrazino[1,2-a][1,3,5]triazin-4-one;
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-3,6-dihydro-pyrimido[1,2-a][1,3,5]triazin-4-one;
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-6,7,8,8a-tetrahydro-3H-pyrrolo[1,2-a][1,3,5]triazin-4-one;
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-3,6,7,8,9,9a-hexahydro-pyrido[1,2-a][1,3,5]triazin-4-one; and
3-(2-Aminomethyl-benzyl)-2-(3-amino-piperidin-1-yl)-3,6,7,8,9,9a-hexahydro-pyrazino[1,2-a][1,3,5]triazin-4-one.
